satsumarx.com
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Investor Resources
  • Contact

Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label
ASCEND Study

« Back
satsumarx.com
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Investor Resources
  • Contact

 ©2023 Satsuma Pharmaceuticals, Inc. All Rights Reserved. | Terms of Use | Privacy Policy

  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Investor Resources
  • Contact